title: Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To evaluate endothelial function via serum asymmetric dimethylarginine (ADMA) levels, paraoxonase 1 (PON1) activity, and brachial artery flow-mediated dilatation (FMD) in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective case-control study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Thirty patients with PCOS with a mean age of 24.33 ± 4.50 years and 30 healthy controls matched for body mass index (BMI) and age.
  
  
  METHODS
  Endothelial function was assessed biochemically with serum ADMA levels and serum PON1 activity and functionally with brachial artery FMD by ultrasonography.
  
  
  METHODS
  Serum ADMA levels, serum PON1 activity, brachial artery FMD, hormonal and biochemical parameters.
  
  
  RESULTS
  Patients with PCOS had higher levels of free testosterone and insulin, and higher waist-hip ratio and Ferriman Gallwey scores when compared with the controls. Fasting glucose and homeostasis model assessment of insulin resistance were not different between the groups. There was no statistically significant difference in ADMA levels between two groups. Serum PON1 activity and brachial artery FMD were statistically significantly lower in women with PCOS. There was negative correlation between ADMA and PON1 in patients with PCOS.
  
  
  CONCLUSIONS
  Serum PON1 activity and brachial artery FMD, as markers of endothelial dysfunction and cardiovascular risk, were statistically significantly lower in women with PCOS compared with healthy controls matched for age and BMI. Endothelial dysfunction may be seen at earlier ages in patients with PCOS.
authors.affiliation: Department of Obstetrics and Gynecology, Kirikkale University, School of Medicine, Kirikkale, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Soyman
authors.forename: Volkan
authors.initials: V
authors.lastname: Noyan
authors.forename: Murat
authors.initials: M
authors.lastname: Tulmac
authors.forename: Aykan
authors.initials: A
authors.lastname: Yucel
authors.forename: Nevin
authors.initials: N
authors.lastname: Sagsoz
authors.forename: Tulin
authors.initials: T
authors.lastname: Bayrak
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bayrak
authors.forename: Erdinc
authors.initials: E
authors.lastname: Cakir
mesh_terms: D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D043303:Aryldialkylphosphatase / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001783:Blood Flow Velocity / Q000502:physiology; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000502:physiology*; D016022:Case-Control Studies; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000453:epidemiology / Q000378:metabolism* / Q000503:physiopathology*; D011446:Prospective Studies; D012307:Risk Factors; D014463:Ultrasonography; D014664:Vasodilation / Q000502:physiology; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006728:Hormones; C018524:N,N-dimethylarginine; D001120:Arginine; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human